Health
News Scan for Apr 19, 2021 – CIDRAP
CARB-X to fund development of bacteriophage-based drug
CARB-X announced today that it is awarding Phico Therapeutics of Cambridge, United Kingdom, up to $5.3 million to develop an intravenous bacteriophage drug to treat ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
The award will support development of Phico’s SASPject PT 3.9 project, which combines engineered bacteriophages with antibacterial small acid-soluble spore proteins (SASPs) to target and inactivate P aeruginosa bacteria….
-
Noosa News21 hours agoRiverfire and 21 other free events on offer
-
General17 hours agoAustralia’s historic decision | The Spectator Australia
-
General8 hours agoFamily of Aboriginal man sues Alice Springs disability provider over death in care
-
General17 hours agoSocial media age verification possible but laden with risks, landmark study warns